Why the study?
Does vasoactive intestinal polypeptide contribute to vagally induced cardioacceleration in conscious dogs?
Population
Conscious dogs (n=11 for intravenous VIP, n=6 for intracoronary VIP)
Comparison
Vasoactive intestinal polypeptide 10 micrograms… vs Baseline measurements before VIP administration
Design
Preclinical
Authors
Loading...
VIP elicits tachycardia and hypotension in dogs; leaves open its role in human vagal cardioacceleration.
Does vasoactive intestinal polypeptide contribute to vagally induced cardioacceleration in conscious dogs?
Vasoactive intestinal polypeptide likely plays a role in the vagal cardiac accelerator system, as it induces tachycardia independent of reflex responses to blood pressure changes.
Albert Roossien (1997) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: